PMLiVE9h
Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma
Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
Too Old to Operate10h
Impact of Multiple Myeloma Treatment on Renal Function Recovery and Prognosis
The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...
appliedclinicaltrialsonline10h
Answering Critical Research Questions in Multiple Myeloma
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...
The Most Meaningful Wedding Gift for Some Couples? Giving Back.
Some couples are restructuring their registries and celebrations to support charitable causes close to their hearts.
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid growth prospects
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...